Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A drug and sustained-release technology, applied in the field of medical materials, can solve the problems of short time, inability to achieve therapeutic effect, and limited amount of drug applied, to promote healing, improve the control of drug release rate and direction, and inhibit smooth muscle. value-added effect
Inactive Publication Date: 2011-06-15
TIANJIN TIANXIANG GLASSWARE
View PDF0 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
In recent years, it has been proposed to prevent restenosis by coating drugs that prevent the proliferation of smooth muscle cells on coronary stents. Due to the single type of drugs coated on the surface of the stent, its effects are limited; and the amount of drugs coated is also very high. Limited, so that the time for the drug to act on the tube wall is relatively short, so the desired therapeutic effect cannot be achieved
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
preparation example Construction
[0033] The preparation method of the compound mushroom functional drink comprises the following steps:
[0034] (1) adding one or more umami flavor agents composed of sodium glutamate, sodium succinate or sodium 5'-inosinate in proportion to the compound mushroom concentrate to become the main ingredient of the compound mushroom functional drink;
[0035] (2) Adding one or more salts composed of sodium chloride, sodium citrate or other salts in the compound mushroom concentrated liquid according to the proportion, to become the main ingredient of the compound mushroom functional drink;
[0036] (3) Add or not add flavoring agents such as ethyl maltol to the compound mushroom concentrate to become the main ingredient of the compound mushroom functional drink;
[0037] (4) Add one or more of sucrose or fructose or fructose syrup or maltose syrup to the main ingredient of the compound mushroom functional drink according to the ratio;
[0038] (5) Adding or not adding sweeteners ...
Embodiment
[0043] (Take 1000kg finished product as an example).
[0044] The components and weight of this compound mushroom functional drink are as follows:
[0045] Compound Mushroom Concentrate 300kg
[0046] Sugar 80kg
[0047] Sour agent 0.4kg
[0048] Salt 0.6kg
[0049] Flavor agent 0.24kg
[0050] Flavor enhancer 0.1kg
[0051] Treated water 680kg
[0052] The above-mentioned compound mushroom concentrate is made by scientifically extracting and concentrating tea tree mushroom as the main raw material together with Hericium erinaceus, Ganoderma lucidum, Shiji mushroom and other edible fungi.
[0053] The above-mentioned sugar material is composed of one or more of sucrose or fructose or fructose syrup or glucose or maltose syrup, and the added weight is 80kg. There is no special requirement for the dosage of the above-mentioned various raw material mixtures, so this embodiment is not necessary. Give specific dosage.
[0054] The above-mentioned salts are composed of one o...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a medicament sustained-release coating. A double-medicament sustained-release coating consists of medicaments and a polymer carrier, wherein the medicaments are used for inhibiting thrombosis and hyperblastosis. The double-medicament sustained-release coating is characterized in that: an external medicament sustained-release coating is applied on the surface of a coronary artery stent; an internal medicament sustained-release coating is placed in a micropore storage groove of the coronary artery stent; the external medicament sustained-release coating is applied on the surface of the coronary artery stent by an ultrasonic atomizing spraying process; the polymer carrier is polylactic acid-glycolic acid (PLGA); and the weight ratio of the polymer carrier to the medicaments is 3:1-10:1. The double-medicament sustained-release coating has the advantages of: 1, guaranteeing that the medicaments can adopt different release sequences and different duration time according to different pathogenesis; 2, maintaining stable blood medicament effective concentration so as to inhibit restenosis of blood vessels and thrombosis; 3, inhibiting proliferation of smooth muscles, reducing thrombosis, promoting healing and improving endothelial function; and 4, greatly improving control of medicament release rate and directivity.
Description
technical field [0001] The invention relates to a coronary stent in the field of medical materials, in particular to a drug slow-release coating. Background technique [0002] Percutaneous balloon intraluminal coronary angioplasty is a new treatment method for treating cardiovascular diseases in recent years. Coronary artery stenting is developed on this basis to treat and prevent coronary stenosis and restenosis. effective method. After the usual metal stent is implanted into the human body, the direct contact of the metal surface with the blood vessel wall and blood stimulates the human body's ability to reject foreign bodies, resulting in hyperplasia of vascular intimal tissue and smooth muscle cells, resulting in restenosis. In recent years, it has been proposed to prevent restenosis by coating drugs that prevent the proliferation of smooth muscle cells on coronary stents. Due to the single type of drugs coated on the surface of the stent, their effects are limited; and...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more